Online inquiry

IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5998MR)

This product GTTS-WQ5998MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ITGAV&ITGB3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001144999.3; NM_000212.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3685; 3690
UniProt ID P06756; P05106
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ5998MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3909MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BCD-135
GTTS-WQ1381MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-981
GTTS-WQ8959MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ1851MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AG1-25
GTTS-WQ13801MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-10933
GTTS-WQ4463MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ13769MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1033
GTTS-WQ3387MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AT-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW